Analytical methods evolve along with product development. In early phases, methods only need to be qualified — proven “fit-for-purpose.” By late development, methods must be validated — comprehensively demonstrated to be reliable under all conditions. The transition from qualification to validation is one of the most important milestones in CMC development.
| Development Stage | Method Status | Notes |
|---|---|---|
| Preclinical / IND-enabling tox | Qualified | Fit-for-purpose testing is acceptable. |
| Phase 1 clinical | Qualified | Demonstrate scientific soundness, sufficient to support patient dosing. |
| Phase 2 clinical | Qualified (with expanded data) | Still acceptable, but regulators expect plans for validation. |
| Phase 3 pivotal trials | Validated | Full validation is a regulatory requirement. Data will support licensure. |
| Commercial release & stability | Validated | Mandatory. Release and shelf-life claims must be backed by validated methods. |
| Analytical Parameter | Method Qualification (Phase 1 / Early Phase 2) | Additional Requirements for Full Validation (Phase 3 & Commercial) |
|---|---|---|
| Overall Goal | Show method is fit for purpose for monitoring CQAs in early development. | Provide comprehensive proof method is reliable, rugged, and suitable for regulatory submission. |
| Documentation | Internal report or technical memo. | Formal, pre-approved validation protocol and a comprehensive validation report suitable for inspection. |
| Accuracy | Limited test (e.g., 3 replicates at 100%). | ICH-compliant: 9 determinations across 3 levels (80%, 100%, 120%), formal acceptance criteria required. |
| Precision | Repeatability only (one analyst, one instrument, n=6 injections). | Intermediate precision mandatory (different days, analysts, instruments); repeatability + inter-day reproducibility compared. |
| Specificity / Selectivity | Confirm separation of main peak from known impurities/excipients. | Forced degradation study required (acid, base, peroxide, heat, light). Must show resolution from all degradants; peak purity proven. |
| Linearity | Basic curve with 3–4 points. | Minimum 5 levels with full regression analysis (R² ≥ 0.999, slope, intercept, residuals). |
| Range | Proposed based on initial linearity data. | Formally declared and justified using linearity, accuracy, and precision results. |
| LOD / LOQ | May not be determined (except rough estimate for impurity methods). | Must be experimentally established and verified for all impurity methods (e.g., S/N = 10 for LOQ). |
| Robustness | Not typically assessed. | Mandatory. Deliberate variation of parameters (pH, temp, flow rate, column lot) to confirm method reliability. |
Summary — What’s Extra for Validation
Moving from qualification → validation adds:
- More Rigor: From “method can work” → “method always works.”
- More Variables: Different analysts, instruments, and days.
- More Stressing: Forced degradation to confirm specificity.
- More Statistics: Formal regression, precision, recovery acceptance criteria.
- More Documentation: Pre-approved protocols and regulatory-ready reports.